PTH control regimens, by DOPPS country and cross-section

  Oral vitD only IV vitD only Oral+IV vitD only Cinacalcet only Cina+oral vitD Cina+IV vitD Cina+oral&IV vitD None
N Ptnts Wgtd % N Ptnts Wgtd % N Ptnts Wgtd % N Ptnts Wgtd % N Ptnts Wgtd % N Ptnts Wgtd % N Ptnts Wgtd % N Ptnts Wgtd %
DOPPS Country DOPPS Cross-section 235 44.7% 8 1.2% 9 1.4% . . . . . . . . 256 52.7%
AusNZ D2(2002)
D3(2006) 263 49.9% 1 0.2% 6 1.2% . . 6 1.2% . . 1 0.1% 240 47.3%
D3(2007) 279 57.0% 3 0.6% 12 2.3% . . 13 2.6% . . 1 0.2% 169 37.3%
D4(2010) 170 52.0% . . . . 15 4.4% 46 15.8% . . . . 75 27.7%
Belgium D2(2002) 183 34.9% 2 0.4% 2 0.4% . . . . . . . . 349 64.4%
D3(2006) 185 36.4% 7 1.3% 42 10.5% . . 13 3.1% . . 1 0.2% 251 48.3%
D3(2007) 189 42.8% 5 1.5% 31 7.4% 5 1.0% 11 4.1% . . . . 170 43.2%
D4(2010) 314 71.4% . . . . 6 1.6% 33 7.6% . . . . 82 19.4%
Canada D2(2002) 262 43.4% 32 6.1% 6 1.1% . . . . . . . . 291 49.4%
D3(2006) 248 47.4% 23 2.8% 16 2.7% 2 0.5% 12 2.0% 1 0.1% 1 0.1% 242 44.5%
D3(2007) 223 54.9% 17 2.2% 11 2.0% . . 15 2.3% 1 0.4% 4 0.6% 172 37.5%
D4(2010) 158 55.0% 13 2.0% 1 0.1% 9 2.9% 9 3.8% 5 1.0% . . 112 35.1%
France D2(2002) 176 36.0% 35 7.4% 4 0.7% . . . . . . . . 301 55.9%
D3(2006) 160 29.4% 16 3.1% 3 0.5% 9 1.8% 51 8.5% 3 0.6% 7 1.0% 299 55.1%
D3(2007) 167 30.5% 10 1.9% 9 1.7% 1 0.1% 78 14.3% . . 8 1.4% 269 50.1%
D4(2010) 210 58.2% 1 0.2% 2 0.5% 14 3.6% 34 9.4% . . . . 97 28.1%
Germany D2(2002) 289 54.1% 24 4.0% 33 5.0% . . . . . . . . 219 36.9%
D3(2006) 321 55.9% 13 2.1% 15 1.8% 6 1.0% 55 9.6% 1 0.1% 7 0.9% 158 28.7%
D3(2007) 342 56.3% 9 1.4% 23 3.1% 5 0.7% 64 10.1% . . 15 1.8% 162 26.6%
D4(2010) 300 56.5% 13 2.1% 17 2.8% 18 3.6% 51 9.5% 4 0.7% 7 1.1% 137 23.7%
Italy D2(2002) 158 26.1% 68 11.6% 6 0.9% . . . . . . . . 338 61.4%
D3(2006) 181 31.6% 51 8.9% 29 5.3% . . 14 3.1% 2 0.3% 6 0.9% 237 49.8%
D3(2007) 179 30.1% 54 9.9% 15 2.5% . . 43 7.3% 2 0.4% 10 1.6% 237 48.2%
D4(2010) 89 20.1% 103 22.9% 7 1.7% 37 8.6% 7 1.6% 37 8.0% 3 0.7% 152 36.4%
Japan D2(2002) 793 44.9% 186 11.3% 24 1.2% . . . . . . . . 760 42.6%
D3(2006) 720 39.3% 305 17.1% 40 2.2% 1 0.1% 1 0.0% 1 0.1% . . 753 41.3%
D3(2007) 735 40.4% 336 17.7% 38 1.7% . . . . . . 2 0.2% 735 40.0%
D4(2010) 589 36.2% 336 18.8% 21 1.2% 39 2.1% 46 2.9% 181 10.9% 11 0.5% 476 27.5%
Spain D2(2002) 121 20.5% 103 16.8% 3 0.6% . . . . . . . . 370 62.2%
D3(2006) 106 15.3% 141 21.6% 16 2.4% 6 1.1% 16 2.2% 4 0.7% 31 4.6% 339 52.1%
D3(2007) 40 6.7% 158 28.6% 8 1.6% 8 1.9% 21 3.9% 5 0.9% 36 6.2% 274 50.2%
D4(2010) 47 7.3% 146 25.5% 5 1.0% 61 12.2% 16 2.6% 85 15.8% 3 0.6% 190 34.9%
Sweden D2(2002) 259 46.5% 95 18.8% 23 4.6% . . . . . . . . 164 30.2%
D3(2006) 237 44.2% 71 12.5% 17 3.6% 4 0.8% 23 4.0% 12 2.4% 7 1.3% 164 31.1%
D3(2007) 208 41.6% 64 12.1% 16 3.1% 5 1.0% 39 7.4% 8 1.8% 18 3.2% 149 29.9%
D4(2010) 205 47.0% 40 8.6% . . 26 5.9% 55 12.2% 17 4.0% . . 95 22.4%
UK D2(2002) 221 40.1% 28 5.2% 8 1.7% . . . . . . . . 292 53.0%
D3(2006) 216 52.4% 4 0.8% 23 4.8% . . 13 2.4% . . . . 182 39.5%
D3(2007) 180 58.0% 5 1.4% 10 2.6% . . 17 3.8% 1 0.2% 1 0.2% 133 33.9%
D4(2010) 221 61.4% 5 1.0% . . 15 3.3% 27 6.0% 1 0.4% . . 103 27.9%
US D2(2002) 53 2.9% 1,180 53.2% 38 1.8% . . . . . . . . 962 42.1%
D3(2006) 34 1.8% 894 48.6% 54 3.1% 25 2.0% 61 3.5% 60 3.4% 199 11.2% 477 26.3%
D3(2007) 15 1.0% 615 47.8% 39 3.2% 8 0.7% 39 2.7% 36 3.4% 225 18.1% 339 23.1%
D4(2010) 155 4.4% 1,574 47.0% 244 7.6% 121 2.8% 29 0.7% 463 14.2% 120 3.8% 616 19.5%

Medications reported as prescribed (not necessarily taken) in previous week, among all patients

Please see additional methodological information in the Data Sources and Methods section.